51,061 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Bought by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 51,061 shares of the company’s stock, valued at approximately $81,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.07% of Zentalis Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Corton Capital Inc. purchased a new stake in Zentalis Pharmaceuticals in the fourth quarter worth $32,000. Captrust Financial Advisors purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at $33,000. Cerity Partners LLC grew its position in shares of Zentalis Pharmaceuticals by 58.7% in the first quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock valued at $33,000 after purchasing an additional 7,579 shares in the last quarter. Prudential Financial Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at $39,000. Finally, Vident Advisory LLC purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at $45,000.

Zentalis Pharmaceuticals Stock Up 1.4%

Shares of ZNTL stock opened at $1.41 on Wednesday. The business has a 50-day moving average price of $1.36 and a two-hundred day moving average price of $1.57. Zentalis Pharmaceuticals, Inc. has a 12-month low of $1.01 and a 12-month high of $5.44. The firm has a market cap of $101.45 million, a P/E ratio of -0.45 and a beta of 1.71.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). As a group, research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Wedbush reissued a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.37.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.